IPG has capitalized on the tremendous growth in the implantable medical device market, growing its revenues by more than 1500 percent since the company was founded in 2004.
“This is a big accomplishment for us,” says Jay Ethridge, CEO of IPG. “Being ranked one of the countrys fastest-growing companies shows that our business model is successful and that IPG is in a position to dramatically improve many aspects of the implantable device market, adding value for all of our stakeholders.”
IPG provides Implantable Device Management for commercial insurance payors, physicians, medical facilities and device manufacturers. Implantable Device Management provides multiple benefits for these stakeholders, including reduced financial risk and simplified billing and reimbursement processes, says the company.
IPGs focus is on large, fast-growth device markets such as cardiology, neurology and orthopedic implants. The cardiology and orthopedic/spine implant markets each exceed $10 billion annually, while the neurological implant market currently at $2.5 billion annually is growing at 20 percent a year. As the U.S. population ages and indications for pacemakers, neurostimulators and joint replacements continue to expand, IPG is positioned to streamline the delivery of these devices and continue its own strong growth.
IPG has recently expanded its reach, partnering with industry leader Medtronic Neuromodulation and global orthopedic manufacturer Smith & Nephew, among others. The company has also signed several key agreements with major commercial insurance payors in the past year.
Learn more about IPG.
